Exclusive Summary

• Mature Development Stage with De-risked Profile: Albenatide (UB778) completed its Phase III clinical trial in 2023. As a late-stage pipeline asset nearing submission, it significantly reduces R&D time and clinical failure risks for global partners.
• Unique MoA and DAC Technology Barrier: Utilizes proprietary Drug Affinity Complex (DAC) technology to merge exendin-4 with recombinant human albumin, effectively resisting enzymatic degradation and distinctively differentiating its platform IP.
• High Efficacy at Low Doses with Exceptional Compliance: Pure glucose-dependent insulin secretion ensures a negligible risk of hypoglycemia. Delivered via a ready-to-use injection pen at an ultra-low 2mg dose subcutaneously once a week, it offers significant glycemic and weight-loss benefits.
• High-value Out-licensing Asset in a $100B Market: Perfectly positioned to capture the booming GLP-1 market (projected to exceed $100B). It is an ideal license-out or co-commercialization target for global pharmas urgently seeking to build or expand their cardio-metabolic portfolios.

Asset Materials

Contact Us for Full Materials